ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Immunology
インパクトファクター: 1.352 5年インパクトファクター: 3.347 SJR: 1.022 SNIP: 0.55 CiteScore™: 2.19

ISSN 印刷: 1040-8401
ISSN オンライン: 2162-6472

巻:
巻 39, 2019 巻 38, 2018 巻 37, 2017 巻 36, 2016 巻 35, 2015 巻 34, 2014 巻 33, 2013 巻 32, 2012 巻 31, 2011 巻 30, 2010 巻 29, 2009 巻 28, 2008 巻 27, 2007 巻 26, 2006 巻 25, 2005 巻 24, 2004 巻 23, 2003 巻 22, 2002 巻 21, 2001 巻 20, 2000 巻 19, 1999 巻 18, 1998 巻 17, 1997 巻 16, 1996 巻 15, 1995 巻 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2013006913
pages 245-281

Immunotherapeutic Treatment of Autoimmune Diabetes

Jae Hyeon Kim
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine; Kyunggi-do 410-773, Korea
Sang-Man Jin
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine; Kyunggi-do 410-773, Korea
Hun Sik Kim
Graduate School, University of Ulsan
Kyoung-Ah Kim
Department of Medicine, Dongguk University International Hospital, Dongguk University School of Medicine
Myung-Shik Lee
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine; Kyunggi-do 410-773, Korea

要約

Type 1 diabetes is a prototypic, organ-specific autoimmune disease. Diverse antigen-specific immunotherapy using insulin or glutamic acid decarboxylase peptides and other immunotherapies, such as antibodies, fusion proteins, cytokines, regulatory T cells, small-molecule inhibitors, nonspecific immune modulators, or dietary modifications, have been attempted in human type 1 diabetes. Some of these immunotherapies delay the onset of diabetes or reduce insulin requirements or blood glucose level in patients with established type 1 diabetes. However, most of these immunotherapies failed to induce complete remission of established type 1 diabetes, which could be due to 1) technical difficulties in the achievement of immune tolerance to diabetic autoantigens or in the inhibition of autoimmune responses to those antigens that can be applied to human patients without significant adverse effects, and 2) markedly reduced β-cell mass at the time of disease onset that should be replenished. This review focuses on the immunological aspects of the disease and its treatment, and data from previous or ongoing human clinical trials using immune-logical measures, and recent results from immunological studies employing animal models are discussed.


Articles with similar content:

Autoimmune Pathogenesis of Multiple Sclerosis: Role of Autoreactive T Lymphocytes and New Immunotherapeutic Strategies
Critical Reviews™ in Immunology, Vol.17, 1997, issue 1
Piet Stinissen, Jef Raus, Jingwu Zhang
Antigen-Specific Tolerance in Immunotherapy of Th2-Associated Allergic Diseases
Critical Reviews™ in Immunology, Vol.33, 2013, issue 5
Paul J. Bryce, Charles B. Smarr, Stephen D. Miller
Role of IL-10 Receptor Signaling in the Function of CD4+ T-Regulatory Type 1 cells: T-Cell Therapy in Patients with Inflammatory Bowel Disease
Critical Reviews™ in Immunology, Vol.38, 2018, issue 5
Shiwa Soukou, Tanja Bedke, Leonie Brockmann, Nicola Gagliani, Samuel Huber, Richard A. Flavell
DNA Double-Strand Breaks Caused by Different Microorganisms: A Special Focus on Helicobacter pylori
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Belmar Kocer-Gumusel, Ming-Wei Chao, Didem Oral, Pinar Erkekoglu
Recognition of Melanoma-Derived Antigens by CTL: Possible Mechanisms Involved in Down-Regulating Anti-Tumor T-Cell Reactivity
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Flavio Arienti, Alessandro Borsatti, Paola Squarcina, Chiara Castelli, Filiberto Belli, Ettore Appella, Francesca Rini, Douglas J. Loftus, Francesco M. Marincola, Giorgio Parmiani, Licia Rivoltini, Carsten Geisler